Evidence map›Paper›PMID 40087896›Full record

ArticleGeriatrics & gerontology international2025

Durability of antibody titers and associated factors after the booster dose of COVID-19 mRNA vaccination in Japanese SARS-CoV-2 infection-naive residents in geriatric intermediate care facilities.

Ayane Kasamatsu, Satoko Ohfuji, Asae Suita, Kyoko Kondo, Hiroyuki Nakata, Tetsuya Kita, Akifumi Deguchi, Mikio Fujimoto, Kazuko Iba, Hideki Sakamoto and 14 more

Abstract readMulticenter Study
In one paragraph

Article in Geriatrics & gerontology international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Ayane KasamatsuDepartment of Public Health, Osaka City University Graduate School of Medicine, Osaka, Japan.ORCID https://orcid.org/0000-0002-5263-0835
Satoko OhfujiDepartment of Public Health, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan.
Asae SuitaDepartment of Public Health, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan.ORCID https://orcid.org/0000-0002-2755-4447
Kyoko KondoManagement Bureau, Osaka Metropolitan University Hospital, Osaka, Japan.
Hiroyuki NakataKeai Long-Term Care Health Facility for the Elderly, Osaka, Japan.
Tetsuya KitaYuai Long-Term Care Health Facility for the Elderly, Osaka, Japan.
Akifumi DeguchiKouseien Long-Term Care Health Facility for the Elderly, Osaka, Japan.
Mikio FujimotoTamagushi-sumire-en Long-Term Care Health Facility for the Elderly, Osaka, Japan.
Kazuko IbaTsukumo Long-Term Care Health Facility for the Elderly, Osaka, Japan.
Hideki SakamotoSayamanosato Long-Term Care Health Facility for the Elderly, Osaka, Japan.
Kaori IwasakaSakuragawa Long-Term Care Health Facility for the Elderly, Osaka, Japan.
Noboru SakamotoYukyuen Long-Term Care Health Facility for the Elderly, Osaka, Japan.
Hikaru SakamotoYukyuen Long-Term Care Health Facility for the Elderly, Osaka, Japan.
Yoshiko YodoiKuwanomi Long-Term Care Health Facility for the Elderly, Osaka, Japan.
Yasutoshi KidoResearch Center for Infectious Disease Sciences, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan.
Yu NakagamaResearch Center for Infectious Disease Sciences, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan.
Ayako KonishiDepartment of Public Health, Osaka City University Graduate School of Medicine, Osaka, Japan.
Emiko MukaiDepartment of Public Health, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan.
Kazuhiro MatsumotoDepartment of Public Health, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan.
Tomoka MatsuuraDepartment of Public Health, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan.
Tetsuo KaseDepartment of Public Health, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan.
Hiroshi KakeyaResearch Center for Infectious Disease Sciences, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan.
Wakaba FukushimaDepartment of Public Health, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan.
Yoshio HirotaClinical Epidemiology Research Center, SOUSEIKAI Medical Group (Medical Co. LTA), Fukuoka, Japan.

Funding

a Grant-in-Aid for Investigation of Promotion of Health Labor Administration (Research Project for Promotion of Policies for Emerging and Re-emerging Infectious Diseases and Immunization) 20HA2001a Grant-in-Aid for Investigation of Promotion of Health Labor Administration (Research Project for Promotion of Policies for Emerging and Re-emerging Infectious Diseases and Immunization) 24HA2007
6 · The paper itself

Abstract

aimElderly adults are at higher risk for severe COVID-19 infection. This multicenter, prospective cohort study assessed immunogenicity after COVID-19 vaccinations in elderly residents compared with staff in geriatric intermediate care facilities. Predictors of lower antibody titers were also examined.

methodsFifty-four residents and 117 staff who had received three doses of the COVID-19 mRNA vaccine between March 2021 and September 2022 were included. Anti-receptor binding domain antibody titers were measured 3-4 weeks and 6 months after the vaccinations. Adjusted geometric mean titers (GMT) were calculated using multivariable linear mixed effects models.

resultsAfter the first dose, residents had a significantly lower adjusted GMT than did staff (115 vs. 267 AU/mL, P < 0.01), whereas the adjusted GMT of residents was comparable to that of staff after the third dose (14 178 vs. 12 159 AU/mL, P = 0.63). However, 6 months later, the adjusted GMT of residents was less than half that of staff (1645 vs. 4302 AU/mL, P < 0.01). In residents, steroid users had a significantly lower adjusted GMT than did steroid nonusers.

conclusionsThe third dose of mRNA vaccine boosted the immune response of elderly residents. However, their antibody titers, particularly in steroid users, were highly attenuated 6 months after the last vaccination. For this population, attention should be focused on additional vaccinations. Geriatr Gerontol Int 2025; 25: 588-597.

Indexed as

Antibodies, ViralCOVID-19COVID-19 VaccinesImmunization, SecondarySARS-CoV-2AgedAged, 80 and overEast Asian PeopleFemaleHomes for the AgedHumansJapanMaleMiddle AgedNursing HomesProspective StudiesAntibodies, ViralCOVID-19 Vaccinesantibody titerbooster doseimmunogenicitylong‐term care facilitymRNA COVID‐19 vaccine

Identifiers

PMID40087896
PMCPMC11973011

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.